Morgan Stanley Downgrades Zentalis Pharma to Equal-Weight, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has downgraded Zentalis Pharma (NASDAQ:ZNTL) from Overweight to Equal-Weight and significantly lowered its price target from $38 to $8.
June 18, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has downgraded Zentalis Pharma from Overweight to Equal-Weight and reduced the price target from $38 to $8, indicating a significant loss of confidence in the stock.
The downgrade from Overweight to Equal-Weight and the drastic reduction in the price target from $38 to $8 by Morgan Stanley suggests a significant loss of confidence in Zentalis Pharma's future performance. This is likely to negatively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100